ADVENZYMES
OVERVALUEDAdvanced Enzyme Technologies Limited
Healthcare · NSE
↓ 30.2% vs fair value
52W Low
₹252
+10.7% from low
52W High
₹366
-23.8% from high
Valuation Gauge
Current Price
₹279
Fair Value
₹214
Fair Value Analysis
₹214
Based on free cash flow projections and balance sheet strength analysis and earnings growth potential for Healthcare sector companies | Sector-cheap: P/E at 24th percentile vs sector peers. | CAUTION: ROCE declining (latest 13.4%) — returns on capital are falling; verify this isn't a value trap.
Cash Flow Analysis
40% weight
Balance Sheet Value
20% weight
Growth Valuation
40% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Healthy
Profitability
ROE of 10.4% is acceptable for Healthcare sector (benchmark: 15%)
Debt & Leverage
D/E ratio of 0.0x is well within the Healthcare sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 20.0x trades at a 87% discount to Healthcare sector median (160x) — attractively valued
Cash Flow
FCF margin of 16.9% — exceptional cash generation (₹108 Cr)
Earnings Growth
5yr EPS CAGR of 3.1% is well below Healthcare sector average of 18.7%
Dividend
Dividend yield of 1.9% provides strong shareholder returns (benchmark: 1.5%)
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
1.7%
Free cash flow / market cap
Revenue Growth (YoY)
+1.8%
Year-on-year revenue change
Profit Growth (YoY)
+10.3%
Year-on-year PAT change
Operating Cash Flow
₹142 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹13.6
P/E Ratio
20x
P/B Ratio
2.1x
ROE
10.4%
ROCE
12.5%
Debt / Equity
0.02x
Beta
0.45
Div Yield
1.9%
FCF (Cr)
₹108 Cr
Revenue (Cr)
₹637 Cr
EPS Growth 5Y
3.1%
Mkt Cap (Cr)
₹3,050 Cr
52W High
₹366.3
52W Low
₹252
Book Value/Share
₹131.1
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹710 Cr | ₹211 Cr | 30.0% | ₹155 Cr | ₹13.61 |
| 2025-03-31 | ₹637 Cr | ₹196 Cr | 31.0% | ₹134 Cr | ₹11.72 |
| 2024-03-31 | ₹624 Cr | ₹206 Cr | 33.0% | ₹137 Cr | ₹11.92 |
| 2023-03-31 | ₹541 Cr | ₹158 Cr | 29.0% | ₹104 Cr | ₹9.45 |
| 2022-03-31 | ₹529 Cr | ₹203 Cr | 38.0% | ₹124 Cr | ₹10.70 |
| 2021-03-31 | ₹502 Cr | ₹232 Cr | 46.0% | ₹151 Cr | ₹13.09 |
| 2020-03-31 | ₹444 Cr | ₹203 Cr | 46.0% | ₹133 Cr | ₹11.58 |
| 2019-03-31 | ₹420 Cr | ₹184 Cr | 44.0% | ₹116 Cr | ₹9.95 |
| 2018-03-31 | ₹391 Cr | ₹165 Cr | 42.0% | ₹94 Cr | ₹8.07 |
| 2017-03-31 | ₹329 Cr | ₹152 Cr | 46.0% | ₹93 Cr | ₹8.20 |
| 2016-03-31 | ₹293 Cr | ₹138 Cr | 47.0% | ₹77 Cr | ₹6.97 |
| 2015-03-31 | ₹222 Cr | ₹91 Cr | 41.0% | ₹51 Cr | ₹4.60 |
| 2014-03-31 | ₹239 Cr | ₹50 Cr | 21.0% | ₹21 Cr | ₹1.85 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Healthcare| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Alpa Laboratories Limited | ₹62.1 | ₹198.5 | +68.7% | 9.4 | 13.4% | FAIRLY_VALUED |
Aster DM Healthcare | ₹670 | ₹1,585.8 | +57.8% | 103.2 | 7.9% | UNDERVALUED |
Unichem Laboratories Limited | ₹300 | ₹592.5 | +49.4% | 7.1 | 12.1% | FAIRLY_VALUED |
Dishman Carbogen Amcis Limited | ₹147.6 | ₹281.2 | +47.5% | 19.5 | 1.9% | FAIRLY_VALUED |
Vimta Labs Limited | ₹414.8 | ₹722.6 | +42.6% | 24.6 | 16.6% | UNDERVALUED |
Morepen Laboratories Limited | ₹38.4 | ₹52.8 | +27.2% | 21 | 10.8% | FAIRLY_VALUED |
Indraprastha Medical Corporation Limited | ₹410 | ₹462.6 | +11.4% | 20 | 20.6% | FAIRLY_VALUED |
Kronox Lab Sciences Limited | ₹133 | ₹130.7 | -1.8% | 16.9 | 24.8% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant